Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Praxis Precision Medicines Inc(PRAX)
Top performer 
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PRAX
09/28/2026: PRAX (4-star) is currently NOT-A-BUY. Pass it for now.
Praxis Precision Medicines is a clinical-stage biotechnology company focused on developing targeted therapies for epilepsy and movement disorders using a proprietary genetics-based platform. The company's primary strength lies in its specialized approach to CNS disorders and a late-stage pipeline led by ulixacaltamide. While this creates a compelling investment story, the company remains pre-commercial, facing significant risks related to clinical trial execution and the need for future capital. It is best suited for growth-oriented investors who can tolerate high volatility. Key developments to monitor include Phase 3 clinical trial results and any potential strategic partnerships that could provide commercial validation.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential linked to clinical breakthroughs but carries significant binary risk. |
| Momentum investor | Strong fit while signal remains positive | The stock can experience significant moves based on clinical trial news flow. |
| Value investor | Weak fit | The company lacks current earnings, revenue, or assets that would satisfy traditional value metrics. |
| Dividend investor | Weak fit | The company is not profitable and does not pay a dividend. |
| Low-risk investor | Weak fit | High volatility and the risks associated with drug development are unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks are prone to sharp price swings based on trial results and regulatory updates. |
| Valuation risk | High | Valuations are highly speculative and dependent on future market projections rather than current cash flows. |
| Competition risk (CNS drug development) | High | The company competes with much larger firms that have greater resources for drug development and commercialization. |
| Business quality | Medium | While the platform and pipeline are technically focused, the company lacks a commercial track record or recurring revenue. |
| Dividend income | Low / none | Investors should not expect any income from this security. |
| Execution risk | High | Success depends entirely on the company's ability to successfully navigate complex clinical and regulatory pathways. |
Price Behavior
Steady Uptrend
The stock demonstrates consistent and steady upward price momentum.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 465.41% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.84B USD | Price to earnings Ratio - | 1Y Target Price 638.68 |
Price to earnings Ratio - | 1Y Target Price 638.68 | ||
Volume (30-day avg) 405.1K shares | Beta 2.78 | 52 Weeks Range 50.31 - 392.70 | Updated Date 09/27/2026 |
52 Weeks Range 50.31 - 392.70 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.97 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development (Pre-commercial) | Research and development of proprietary ion channel therapeutics. | Praxis does not currently sell products; it spends money to develop potential drugs that it hopes to sell in the future. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7.12B | Price to Sales(TTM) 144.69 |
Enterprise Value 7.12B | Price to Sales(TTM) 144.69 | ||
Enterprise Value to Revenue 110.91 | Enterprise Value to EBITDA -6.86 | Shares Outstanding 27.92M | Shares Floating 24.08M |
Shares Outstanding 27.92M | Shares Floating 24.08M | ||
Percent Insiders 0.28 | Percent Institutions 123.2 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Praxis Precision Medicines Inc
Exchange NASDAQ | Headquarters Boston, MA, United States | ||
IPO Launch date 2020-10-16 | President, CEO & Director Mr. Marcio Silva De'Souza M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 168 | Website https://praxismedicines.com |
Full time employees 168 | Website https://praxismedicines.com | ||
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.